What is the remission success rate of vedolizumab (Entyvio) versus ustekinumab (Stelara) in a patient with ulcerative colitis limited to the distal rectum who has failed adalimumab (Humira), has elevated triglycerides, and has primary sclerosing cholangitis with normal liver enzymes?

Vedolizumab (Entyvio) appears to be the more appropriate choice for this patient, though both agents have modest efficacy after anti-TNF failure.

Key Recommendation Based on Patient-Specific Factors

For this patient with distal UC who has failed Humira, vedolizumab is the preferred option over ustekinumab. The 2025 British Society of Gastroenterology guidelines provide moderate certainty evidence for vedolizumab versus low certainty evidence for ustekinumab in UC 1. More importantly, the patient's elevated triglycerides and PSC make vedolizumab's gut-selective mechanism advantageous, as it avoids systemic immunosuppression that could theoretically worsen metabolic parameters.

Expected Remission Rates After Anti-TNF Failure

Vedolizumab (Entyvio):

• Clinical remission at Week 16: Approximately 38-40% in anti-TNF exposed patients 1
• Maintenance remission at 1 year: The treatment effect is notably small in patients with prior anti-TNF exposure 1
• Important caveat: The 2025 BSG guidelines explicitly state "the treatment effect is small in patients with prior anti-TNF therapy exposure" and recommend "caution is used in patients with prior infliximab failure" 1

Ustekinumab (Stelara):

• Clinical remission at Week 8: 15.5-15.6% (induction) 1
• Maintenance remission at Week 44: 38.4% (every 12 weeks) to 43.8% (every 8 weeks) 1
• Overall certainty: Low for small benefit 1

Critical Evidence from Direct and Indirect Comparisons

The most relevant real-world data comes from a 2024 multicenter study directly comparing these agents in anti-TNF exposed UC patients 2. After propensity score adjustment:

• Steroid-free clinical remission at Week 16: Vedolizumab 38.0% vs Ustekinumab 40.3% (no significant difference, p=0.85)
• Endoscopic remission at Week 16: Vedolizumab 5.3% vs Ustekinumab 17.5% (aOR=3.77, p=0.018) - ustekinumab superior
• Histological remission at Week 16: Vedolizumab 2.1% vs Ustekinumab 11.1% (aOR=5.85, p=0.012) - ustekinumab superior

However, this study found that primary failure to at least one biologic was significantly associated with decreased response to ustekinumab (OR=0.31, p=0.018), while no such predictor existed for vedolizumab 2.

Why Vedolizumab is Preferred for THIS Patient

1. Distal disease location: With UC "mostly in distal rectum," this patient may benefit from vedolizumab's gut-selective mechanism. The 2020 AGA guidelines note vedolizumab's moderate certainty evidence 3.

2. Elevated triglycerides: Vedolizumab's gut-selective α4β7 integrin blockade avoids systemic metabolic effects. Ustekinumab's IL-12/23 inhibition has broader systemic immunologic effects.

3. PSC with normal liver enzymes: While both agents are safe in PSC, vedolizumab's gut-selective mechanism theoretically provides better gut-liver axis targeting. The drug label shows no hepatotoxicity signals 4.

4. Pattern of prior failure: If the patient had primary non-response to Humira (adalimumab), the 2020 AGA guidelines suggest ustekinumab or tofacitinib over vedolizumab 3. However, if secondary loss of response occurred, vedolizumab remains appropriate 5.

Practical Dosing Considerations

Vedolizumab:

• Induction: 300 mg IV at weeks 0,2,6
• Consider additional dose at Week 10 if inadequate response at Week 6 6
• Maintenance: 300 mg IV every 8 weeks (standard) or every 4 weeks if needed
• Assess response at 8-14 weeks 5

Ustekinumab:

• Induction: ~6 mg/kg IV (weight-based)
• Maintenance: 90 mg SC every 8 weeks (preferred over every 12 weeks based on higher remission rates: 43.8% vs 38.4%) 1

Safety Profile Relevant to This Patient

Both agents show similar safety profiles with no significant differences in serious infections or adverse events compared to placebo 1, 4. Vedolizumab's most common adverse reactions include nasopharyngitis, headache, and arthralgia 4. Neither agent shows concerning hepatotoxicity that would be problematic with PSC 4.

Common Pitfalls to Avoid

1. Don't assume equivalent efficacy: While clinical remission rates are similar, ustekinumab shows superior endoscopic and histological healing 2, which may matter for long-term outcomes.

2. Don't ignore prior biologic exposure pattern: Multiple prior biologic failures significantly reduce ustekinumab's effectiveness 2, 7.

3. Don't use standard 12-week dosing for ustekinumab: The evidence clearly shows every 8 weeks is superior to every 12 weeks for maintenance 1.

4. Don't delay dose optimization: For vedolizumab, consider every 4-week dosing if suboptimal response on every 8-week dosing 5.

Bottom Line for This Patient

Start with vedolizumab given the distal disease location, metabolic concerns, and PSC. Expect approximately 38-40% chance of steroid-free clinical remission at 16 weeks, but recognize this is modest efficacy. If the patient had primary non-response (not just inadequate response) to Humira, consider ustekinumab instead, as it may provide better deep remission (endoscopic/histological) despite similar clinical remission rates. Assess response at 8-14 weeks and be prepared to dose escalate or switch if inadequate response.